Background: This study evaluates the effect of a program combing specialized medication packaging and telephonic medication therapy management on medication adherence, health care utilization, and costs among Medicaid patients.
A s costs associated with medication use and medicationrelated problems continue to rise in the United States, 1 there has been a greater focus on identifying effective methods for enhancing quality of care while simultaneously reducing costs. Medication therapy management (MTM), defined as "a distinct service or group of services that optimize therapeutic outcomes for individual patients," 2 has been identified as 1 promising method. Pharmacists are the most commonly utilized provider for part D MTM programs 3 and these services represent an opportunity for pharmacists to provide more direct patient care and expand the scope of the profession's role beyond medication preparation and dispensing. 4 Core elements of MTM include: (a) completing a medication therapy review to identify medication-related problems; (b) developing a personal medication record and "action plan" for the patient; (c) implementing interventions and/or providing referral(s) when warranted; and (d) providing follow-up care. 5 In recent years, MTM has become more integrated into Medicare, because all part D sponsors are required to offer this service to optimize medication use through promoting patient understanding of medications, enhancing medication adherence, and preventing/detecting adverse drug events. 6 In addition to part D programs, MTM services have been provided to private-pay patients, through employer-sponsored insurance programs, and through statesponsored programs such as Medicaid. Although published studies examining MTM interventions provided by pharmacists have yielded positive results, [7] [8] [9] [10] [11] questions remain regarding the optimal design for maximizing positive health outcomes. Furthermore, few published reports have described evaluations of MTM services in state Medicaid populations. [12] [13] [14] [15] [16] Typically, MTM programs have targeted specific disease states, 13 used process measures or surrogate outcomes as endpoints, 12, 15 and used self-reported cost avoidance estimates 16 rather than actual costs.
This report describes a program evaluation of a pharmacy service delivery model that combined a telephonic MTM service with specialized medication packaging. Combining strategies for improving medication adherence including specialized medication packaging and telephonic MTM has been supported by recent reviews. 17, 18 The current program is intended to: (a) promote medication adherence through specialized packaging during the drug dispensing process; and (b) engage pharmacists and patients in discussions to facilitate identification and resolution of medication-related problems and concerns. The current evaluation builds on existing literature by examining the effect of this pharmacy service model on medication adherence, health care utilization, and health care spending in a cohort of Medicaid beneficiaries.
METHODS

Program Description
A private pharmacy services company provided a proprietary multifaceted program that combined both specialized medication packaging with telephonic MTM provided by pharmacists. The program was intended to obviate the need for multiple pharmacy trips, simplify and improve accessibility to prescription meds, and improve the overall quality of the medication regimen. The specialized packaging organized prescription medications, over-the-counter medications, and vitamins into presorted packets (with all medications combined) that were clearly marked with the date and time that the dose(s) is to be taken. Packets are assembled into a dispensing box containing a 28-day supply delivered by mail to the patient or caregiver's home. Transfer of the patients' medications typically occurred over a period of 1-2 months during which the patient profile was built, all new and existing prescription records were transferred to the program from all other pharmacies, and the patients' prescriptions were synchronized to enable dispensing of all medications on the same day of each month. Before each monthly dispensing box was mailed, a proactive telephone call to the patient by a pharmacy technician occurred 1-2 weeks prior to verify the medication regimen and update any changes.
In addition, an MTM program was conducted through telephone for all program patients by pharmacists who received special training in the delivery of MTM along with a manual detailing the components of MTM based on national recommendations. 5 During the initial MTM phone call, the pharmacist reviewed the entire drug profile with the patient and/or their caregiver(s) to verify the safety of prescription combinations, identify any drug-related therapy problems, and develop a plan to resolve any identified problems (eg, avoid/mitigate adverse effects, add/increase medications to treat conditions, remove/decrease unnecessary medications). 19 The pharmacist liaised with other health care providers or initiated further follow-up contact with the patient, as needed, to resolve problems and improve the effectiveness of the overall medication regimen. Program patients paid no additional fees to receive the program, and out-of-pocket copayment costs for medications received through the program were identical to copayments for medications received through traditional community pharmacies.
Program Enrollment
Beginning on November 1, 2008, the program was offered as a covered benefit for Indiana Medicaid members under their managed-care program, which provides comprehensive care coordination, disease management, and utilization management for members who are aged, blind, or disabled; including individuals with physical disabilities as well as intellectual and developmental disabilities and the seriously mentally ill population. 20 During the third quarter of 2008, Medicaid selected members for the program. Eligible members: (a) were enrolled, as of July 1, 2008, in the Medicaid managed-care program; (b) remained continuously eligible for this service through the covered benefit start date (November 1, 2008); and (c) received Z5 Medicaid-covered prescription medications during the third quarter of 2008. Members who received home-based or community-based waiver services were ineligible (Figs. 1 and 2).
During the first 6 months of the program, telephone calls were placed by Medicaid to members in randomized block sequence, according to their zip code of residence. During the call, the program was explained and members who expressed immediate interest were transferred to the enrollment center. Members who expressed some interest provided their contact information for subsequent follow-up. Three telephone calls were placed during varying days and times before a member was classified as unreachable. In addition, a letter was mailed to all eligible members describing the program and encouraging participation by contacting the enrollment center directly. Entry to the program was voluntary and required eligible members to opt in. Once enrolled, members could opt out of the program at any time for any reason.
Design
The authors were part of an evaluation team hired by Medicaid to conduct an evaluation of program effectiveness. We used a retrospective cohort design to evaluate medication adherence and utilization of health services and costs during a 12-month program period among eligible Medicaid participants who opted to enroll in the program compared with those who did not. For the retrospective cohorts, selection of patients into the program cohort included members who opted into the program and received at least 1 month of medication dispensing between November 1, 2008 and June 30, 2009 . The comparison (usual care) cohort included all eligible Indiana Medicaid members who were offered participation in the program but chose not to participate. Patients were excluded from the study cohorts if they were (a) less than 18 years of age at the time of enrollment; (b) grouped into Medicaid aid categories for children, pregnant women, or aged (ie, members 65 years of age and older at time of enrollment or expected to turn 65 during the follow-up period); (c) receiving hospice care in the year prior to enrollment; or (d) died during the follow-up period.
All individuals were followed for 12 months from an index date; for the intervention cohort, this date was defined by the date of the first prescription claim from the program after enrollment. For the usual care cohort, patients were randomly allocated to an index date that coincided with the proportion of intervention participants with index dates during each month of the enrollment period. The study was approved by the Indiana University and Purdue University Indianapolis institutional review boards and the Veterans Affairs Research and Development Committee.
Data Sources and Data Collection
Data for the entire cohort were extracted from Indiana Medicaid eligibility, medical, and prescription claims files. Eligibility files included data characterizing age, sex, race, marital status, date of death, regional location of residence, and type of Care Select plan. Medical and pharmacy claims data were extracted for 12 months before and 12 months after the index date for each patient. Medical claims data included hospitalization dates, emergency department (ED) visit dates, outpatient treatment dates, paid claim costs, and primary and secondary diagnosis codes according to the International Classification of Diseases, Ninth Revision (ICD-9). ICD-9 codes were used to estimate medical comorbidities using the Elixhauser method. 21 Prescription claims data included drug name, national drug code number, American Hospital Formulary Service pharmacologic-therapeutic classification code, quantity dispensed, dates of fills and refills, paid claim costs, and name of dispensing pharmacy. Additional data on the number of MTM phone contacts and the number and type of identified drug-therapy problems (DTP) for the program cohort was extracted from the telephonic MTM software (Assurance-Medication Management Systems; Eden Prairie, MN). This software was used by the pharmacists as an electronic chart to record their patient care activities.
Measured Outcomes
Outcomes included medication adherence, health care utilization and total health care costs from the Medicaid perspective, and descriptive information related to the MTM program. Medication adherence was evaluated using 2 measures, compliance and persistence, as defined by the International Society Pharmacoeconomic and Outcomes Research. 22 For both measures, prescription medications and therapeutic classes that were used for chronic disease treatment (eg, hypertension, diabetes, asthma) were included, whereas medications for acute conditions, nonprescription medications, or medications intended for as-needed use were excluded (list available from the authors). Medication compliance was computed using the medication possession ratio (MPR) defined by Steiner and Prochazka 23 as a continuous, multiple-interval measure of medication availability. To account for medication switches and concurrent therapy, an average of all drugs' MPRs within a therapeutic class was computed to produce 1 averaged MPR for each class; the average MPR was then dichotomized with noncompliance defined as <0.8 and compliance defined asZ0.8. 24 If the average MPR was >1.0, it was truncated at 1.0. Medication persistence was calculated using the proportion of days covered (PDC). The PDC was sensitive to gaps of r15 days for all drugs and was chosen to reflect one half of the usual days' supply of medication for most prescriptions (eg, 30-d supplies). The PDC was dichotomized using the Z0.8 threshold for persistence. 25 Health care utilization outcomes were defined as the number of all-cause hospitalizations and all-cause ED visits as well as both hospitalizations and ED visits for ambulatory care sensitive conditions. 26 Total costs represented the sum of paid claims for inpatient, outpatient, ED, and medications filled under the Medicaid system. A 90-day lag period was used to account for claims lags in the data; this period was estimated by Medicaid to provided adequate time to capture >95% of all claims.
Statistical Analyses
This study compared the program cohort to the usual care cohort during the 12-month follow-up period using an intent-to-treat analysis. To compare medication adherence, a multivariate logistic regression model was constructed for each therapeutic medication class. Separate models used the dependent variable of compliance or persistence (ie, MPR or PDCZ0.8) with the independent variables of age, sex, ethnicity, marital status, county of residence, type of care management, total number of Elixhauser comorbidities, 21 and number of unique prescriptions medications taken during the 12-month preindex period. For health care utilization, separate multivariate logistic regression models were constructed for each of the dependent variables for the 6-and 12-month periods after the index date. Independent variables included those listed above, along with the number of preindex ED visit(s) and the number of preindex hospitalization(s).
Similar multivariate regression models were constructed to examine total health care costs in the 6-and 12month postindex periods. To address issues of skewness and violations of normality assumptions, a generalized linear model with a gamma distribution and a log-link function was used. Estimated parameters were obtained using the maximum likelihood technique, [27] [28] [29] and adjusted results are presented as cost ratios with 95% confidence interval (CI) estimates. A-priori significant differences between groups were set for P < 0.05. Analyses were also conducted for subgroups with specific comorbid conditions: diabetes, hypertension, chronic pulmonary disease (asthma and chronic obstructive pulmonary disease), heart failure, and mental health (depression and psychoses). Finally, to assess treatment fidelity, an analysis was conducted for a subgroup of the program cohort that received "an adequate dose of the 
RESULTS
Characteristics of the Study Cohorts
Medicaid members (n = 19,864) eligible for enrollment in the program were mailed a recruitment letter and/or received a telephone call (Fig. 2) . Ultimately, 1007 members were included in the program cohort and 13,614 were included in the usual care cohort. The program cohort (Table 1 ) had a greater proportion of women and African Americans than did the usual care cohort (P < 0.05). The average number of comorbid conditions was similar in both groups, but the proportion of patients with diabetes, chronic pulmonary disease, obesity, and hypertension was higher in the program cohort (P < 0.05). The proportion of patients with alcoholism and psychoses was higher in the usual care cohort (P < 0.05).
Program Fidelity and MTM
Individuals enrolled in the program received an average of 13.6 ± 9.5 prescription fills during an average of 6.4 ± 3.5 months, and the average number of months that participants continuously received at least 1 medication (without a gap of 15 d from the previous fill) from the program was 5.4 ± 3.5. Among the 1007 participants enrolled in the program, MTM pharmacists made 3545 telephone calls to 684 participants during the 12-month follow-up period and averaged 3.5 ± 3.5 telephone calls per participant (range, 0-16). There were 323 participants who received no telephone call for reasons including patient refusal, unable to be contacted, and an information technology malfunction that prevented patients from being loaded into the queue for outbound phone calls. The average number of DTP per participant identified by the pharmacists was 31.6 ± 30.2 (range, 1-141) with a documented complete resolution for 3.8% of all problems.
Medication Adherence
Results for medication compliance and persistence (Table 2) reveal that across each of the 10 therapeutic classes, the proportion of patients who had an MPRZ0.8 and/or a PDCZ0.8 was significantly higher in the intervention cohort compared with usual care. The overall measure that includes Z1 medications within each therapeutic class demonstrated that the proportion of patients who were compliant [80.8% vs. 36.4%; odds ratio (OR) = 7.8, 95% CI, 6.5-9.4, P < 0.001] and/or persistent (56.9% vs. 22.1%; OR = 5.1, 95% CI, 4.4-6.0, P < 0.001) was more than twice as high in the intervention cohort when compared with usual care.
Health Care Utilization
Six month all-cause adjusted inpatient utilization was marginally less in the intervention cohort compared with the usual care cohort (OR = 0.73, 95% CI, 0.54-1.00, P = 0.05; Table 3 ). There were no other significant differences for any of the adjusted endpoints, at 6 or 12 months, between the 2 groups. Among the subgroup of participants with Refers to the initial disposition of each subject regarding their receipt of a telephone call for recruitment into the program; A, all subjects in both cohorts were contacted through the telephone call and initially agreed to participate in the program; those in the program cohort enrolled in the program, whereas those in the usual care cohort did not enrolled in the program despite initially agreeing to participate; B, all subjects in both cohorts were contacted through the telephone call and initially refused to participate in the program; those in the program cohort ultimately enrolled in the program despite their initial refusal to participate (possibly because of the mailed invitation), whereas those in the usual care cohort did not enroll in the program; C, all subjects in both cohorts were unable to be contacted through telephone; those in the program cohort ultimately enrolled in the program (possibly because of the mailed invitation), whereas those in the usual care cohort did not enroll in the program; D, all subjects in both cohorts were never attempted to be contacted through telephone; those in the program cohort ultimately enrolled in the program (possibly because of the mailed invitation), whereas those in the usual care cohort did not enroll in the program. z Managed-care stratification plans are categorized from 1 to 4, with 1 representing the least care management provided to Medicaid members and 4 representing the most intense care management provided to members.
y Calculated from the Elixhauser comorbidity index. 21 diabetes, the adjusted odds of all-cause ED visits at 6 months for intervention patients was 27% less than those in the usual care cohort (OR = 0.73, 95% CI, 0.54-0.97, P < 0.05); however, this effect was not sustained at the 12-month follow-up. Similar analyses for participants with hypertension, chronic pulmonary disease, heart failure, and mental health did not reveal significant differences between the intervention and usual care cohorts. In addition to the intention-to-treat analysis, intervention effects were evaluated by the "dose" of the intervention that patients received; participants who received Z6 months of continuous specialized medication packaging plus Z3 MTM telephone contacts (n = 372) did not differ from the usual care group with respect to health care utilization.
Health Care Costs
Adjusted total cost for the intervention cohort at the 12-month postindex period was 84% higher than the usual care cohort (Table 4 ; P < 0.0001). Adjusted results demonstrate higher expenditures for outpatient, prescription, and total costs for the intervention cohort compared with the usual care cohort. Costs for inpatient and ED care did not differ between cohorts. Analyses of the subgroup that received Z6 months of continuous specialized packaging plus Z3 MTM telephone contacts and comorbid subgroups such as diabetes, hypertension, chronic lung disease, heart failure, and mental health produced similar nonsignificant findings.
DISCUSSION
This intervention program combined several strategies for improving medication adherence and medical outcomes, including specialized medication packaging, synchronization of dispensing along with home delivery, and telephonic MTM provided by pharmacists. 17, [30] [31] [32] Results of this program evaluation were mixed-although measures of medication adherence were significantly higher in the intervention cohort, there were minimal differences in associated ED visits and hospitalization outcomes. Studies that have improved medication adherence have generally been associated with some improvements in health care outcomes 33 ; although a recent systematic review suggests that "even the most effective interventions do not translate into large improvements in adherence and treatment outcomes," with effect sizes that are variable for interventions and not consistently related to adherence measures. 17, 18 The findings from the current study support these assertions. Most studies of interventions to improve medication adherence have evaluated intermediate outcomes such as blood pressure, low-density lipoprotein (LDL), or hemogloblin A1c 17 ; while these are clinically important, the temporally distant causal link with associated health care utilization is less well established. Few studies have evaluated major outcomes such as ED visits, hospitalizations, morbidity, or mortality. 17, [34] [35] [36] The lack of improved health care outcomes, despite large improvements in estimates of medication adherence in the current study, may be explained by several study design and w Estimated using multivariate logistic regression models for each therapeutic medication class. Separate models used the dependent variable of compliance or persistence with the independent variables of age, sex, ethnicity, marital status, county of residence, type of care management, total number of Elixhauser comorbidities, 21 and number of unique prescriptions medications taken during the 12-month preindex period. CI indicates confidence interval; MPR, medication possession ratio; PDC, proportion of days covered.
program implementation factors including the duration of follow-up, the method of medication delivery and assessment of medication adherence, the design and execution of the telephonic MTM program, a nonrandomized design, and other study limitations including the targeted population.
For an intervention designed to improve medication adherence, the downstream effect on outcomes such as blood pressure, LDL, and hemogloblin A1c often can be captured with 6-12 months of monitoring; however, the more distal outcomes, such as ED visits and hospitalizations might require longer periods of follow-up. Specifically, in this evaluation, the timeline for patients to begin receiving all medications synchronized into a single home delivery box along with the initial MTM session occurred 3 months after program enrollment. A previously published evaluation of a multicomponent intervention using specialized packaging and telephonic education and monitoring by pharmacists found that medication adherence improved at 6 months and was associated with improved systolic blood pressure and LDL 37 ; however, the study did not evaluate long-term endpoints such as hospitalization. In contrast, in a 2-year study of periodic telephone counseling provided by pharmacists, medication adherence was improved and associated with a 41% reduction in all-cause mortality. 36 21 number of unique prescriptions medications taken during the 12-month preindex period, preindex ED visit(s), preindex hospitalization(s), preindex medical and pharmacy costs, using Gamma distribution with a log-link function.
CI indicates confidence interval.
This intervention program used a proactive medication refill process, synchronization of refills, and home delivery. Although the claims-based measures of medication adherence demonstrated significant improvements, these measures may overestimate true medication taking behavior-one cannot assume that simply providing more medication and making it accessible to the patient is synonymous with increased medication consumption (ie, enhanced adherence). Although the concept of specialized packaging and refill synchronization is attractive and likely reduces many of the burdens associated with medication acquisition for patients, the observed lack of correlation between our measures of adherence and health care utilization suggest a need for measurement studies to estimate the extent to which specialized packaging and synchronization translates into actual changes in medication consumption. Furthermore, studies are needed to determine the independent effects of MTM and specialized packaging. In the study reported here, the intervention elements were delivered in combination. For some patients the packaging might be more beneficial-for example, patients for whom the medical regimen is stable. 38 For patients whose regimens are in flux, prepackaging (eg, a month's supply) might not offer a logical approach to medication management. On average, participants continuously received medications an average of 5.4 months, and fewer than 4% of all participants received all 12 months of continuous specialized medication packaging, suggesting a need to examine the reasons underlying lack of fidelity to the program in this population.
The telephonic MTM component of the intervention provided a method for communication between the pharmacist, the patient, and the patients' other health care providers to identify and resolve DTPs. The MTM program reached approximately two thirds of the intervention patients, and pharmacists spoke with these patients an average of 3.5 times during the follow-up period. During the calls, pharmacists identified a large number of DTPs (n = 22,187), yet only a small proportion (3.8%) of the DTPs were documented as having been fully resolved at the 12-month study completion. Evaluation of an MTM program in Connecticut reported cost savings and greater therapeutic goal achievement when approximately 80% of DTPs were resolved by pharmacists. 39 A likely barrier to DTP resolution in the current intervention program is insufficient collaboration between participating pharmacists and patients' physicians. Without active responses by physicians to identified DTPs, it is doubtful that benefits can be fully achieved. Pharmacists participating in the Connecticut project 39 provided MTM onsite at the medical office and had access to patients' medical and pharmacy records that assisted them in identifying and resolving DTPs. In addition, evaluation of a Minnesota Medicaid MTM program 14 determined that the highest DTP resolution rates were among pharmacists practicing in an integrated care delivery system in close proximity to prescribers. In that study, 18% of resolved DTPs required collaboration with prescribers. 14 Similarly, an evaluation of MTM services provided to Blue Cross/Blue Shield beneficiaries found that 22% of resolved DTPs required collaboration between the pharmacist and physician. 9 Closer examination of the DTPs in the current evaluation suggests that 27.3% of the DTPs involved communication and collaboration with the prescriber to resolve the problem. Although the MTM system captured data relevant to telephone contact with patients, limited data were captured to further characterize communication with prescribers. This may have been an even greater challenge in the current population as we found a very high percentage of patients were utilizing the emergency department; this may indicate limited utilization of primary care physicians with whom the pharmacists may have attempted to contact with medication recommendations.
Accessing primary care physicians and establishing collaborative working relationships have been cited as barriers to MTM provision. 40 Factors associated with developing collaborative relationships with physicians, such as establishing bidirectional communication and building trust through consistent provision of high-quality recommendations have been identified; however, these aspects of relationship development take time to mature and generally require active outreach by the pharmacist. [41] [42] [43] [44] Furthermore, in the current study model of telephonic MTM, collaboration with prescribers and outreach efforts to enhance collaboration can be especially difficult as the pharmacist and physician are practicing at a distance and the physician may be unfamiliar both with the individual pharmacist and with the overall concept of MTM. Maturation of the MTM program may be needed to accurately assess the full effect of these programs, whereas the current evaluation included early implementation of the MTM program.
Limitations of the study should be considered. First, the nonrandomized study design may produce selection bias and unobserved differences such as the healthy user effect that cannot be adjusted for in the analyses. 45 Second, given the Medicaid populations' socioeconomic difficulties and related challenges with access and routine use of primary care, this type of pharmacy program may not effectively change this populations' health care seeking behaviors. In fact, the state of Indiana had created a separate robust fulltime care management program that found similar limited results in the ability of their program to modify Medicaid members' behavior and realize cost savings. 20, 46 It is possible that the program evaluated in the current study may be more applicable to other populations such as an ambulatory, geriatric program like Medicare part D but future studies are required.
CONCLUSIONS
The program improved estimates of medication adherence, but the measurable effect on health care utilization and nonpharmacy costs at 6 and 12 months was not different from the usual care group. Reasons for these findings may reflect differences in the delivery of the specialized packaging and the MTM program, health care behaviors in this Medicaid cohort, unadjusted confounding, and time required for the benefit of the intervention to manifest. Further rigorous studies are required to understand disease-specific changes in health care utilization and appropriateness of MTM programs in the Medicaid population.
